<DOC>
	<DOCNO>NCT01683981</DOCNO>
	<brief_summary>Due vasodilatory property NO , one therapeutic approach IPAH oral use nitric oxide precursor ( 10 ) . Efficacy L-arginine well-documented current literature paucity data regard L-citrulline- malate . Hence , study evaluate therapeutic efficacy L-citrulline- malate two category patient pulmonary hypertension ( IPAH , Eisenmeger syndrome ) . This randomized clinical trial utilizes 6-minute walk , pro BNP level echocardiographic index indicator functional improvement patient .</brief_summary>
	<brief_title>Exercise Capacity Quality Life Patients With PPH Receiving Short Term Oral L-Citrulline Malate</brief_title>
	<detailed_description>Pulmonary vascular tone maintain action vasoprotective compound include nitric oxide ( NO ) ( 1 ) .NO synthesize endogenously body via L-arginine NOS-independent mechanism anion nitrite ( NO2- ) ( 2,3 ) .Nitric oxide ( NO ) cause cyclic guanosine monophosphate-mediated vasodilatation pulmonary vasculature . Endogenous NO also produce metabolism citrulline ; amino acid generate urea cycle ( 4 ) . NO critical normal development pulmonary vasculature loss vasodilator factor subsequent endothelial dysfunction propose one possible explanation development pulmonary hypertension ( 1 ) . From clinical standpoint , pulmonary hypertension common complication chronic obstructive pulmonary disease ( COPD ) .Its presence associate short survival bad clinical outcome . In set COPD , pulmonary hypertension tend moderate severity progress slowly . Recent investigation demonstrate endothelial dysfunction change expression endothelial-derived mediator regulate vascular tone cell growth pulmonary artery patient mild disease ( 5 ) . Pulmonary vascular involvement congenital heart disease like Eisenmeger syndrome another important category patient PAH . In congenital disease pulmonary vascular involvement follow period pulmonary resistance low pulmonary blood flow high ( 6 , 7 , 8 ) . Finally , Idiopathic pulmonary hypertension ( IPAH ) third category patient . IPAH unknown etiology characterize progressive obliteration small medium size pulmonary artery ; elevation pulmonary arterial pressure , increase pulmonary vascular resistance . Presence pathology eventually lead right heart failure death ( 9 ) .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Eisenmenger Complex</mesh_term>
	<criteria>patient le 70 year old , patient sixminute walk distance 100 meter ( ) , mean pulmonary arterial pressure ( PAP ) â‰¥ 25 mmHg rest assess right heart catheterization ( RHC ) ( 11,12 ) . patient 70 year old , patient sixminute walk distance le 100 meter ( ) , active pulmonary extra pulmonary infection , serious coronaropathy and/ ventricular dysfunction , significant renal illness and/or hepatitis , detect immunosuppressive illness , carrier know neoplasias , pregnancy , lack family support , psychosocial problem , drug alcohol abuse , noncompliance establish medical protocol .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Idiopathic Pulmonary Arterial Hypertension</keyword>
	<keyword>Eisenmenger Syndrome</keyword>
	<keyword>Exercise Capacity</keyword>
	<keyword>Quality Life</keyword>
</DOC>